A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Clinical trial NCT06550895 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06550895
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-16
- Primary completion
- 2027-08-26
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.